India Glycols Ltd Demerger Update

Effective Date: Tuesday, September 1, 2026
Record Date: Wednesday, September 2, 2026

Reader Takeaway: Demerger proceeds with NCLT approval; shareholders get new shares in two entities.

What just happened

India Glycols Ltd has announced the crucial dates for its demerger. The National Company Law Tribunal (NCLT), Allahabad Bench, has sanctioned the scheme of arrangement. The company's Board of Directors confirmed the timeline on August 21, 2026.

Why this matters

This marks a significant step towards the completion of the demerger, which will create two separate listed entities. Shareholders will soon be allocated shares in the newly formed companies, potentially unlocking value and allowing for focused business operations.

The backstory

India Glycols Ltd is undergoing a strategic restructuring to separate its pharmaceutical and spirits businesses from its core chemical operations. The NCLT's approval was a key hurdle that has now been cleared.

What changes now

Following the effective date of September 1, 2026, the demerged companies, Ennature Bio Pharma Limited and IGL Spirits Limited, will become distinct entities. The record date of September 2, 2026, will determine which India Glycols Ltd shareholders are eligible for the share allocation in the new companies.

Share Entitlement Ratios

• Shareholders will receive 1 equity share of Ennature Bio Pharma Limited (face value Rs 5) for every 3 equity shares of India Glycols Ltd (face value Rs 5) they hold.
• Shareholders will receive 1 equity share of IGL Spirits Limited (face value Rs 5) for every 1 equity share of India Glycols Ltd (face value Rs 5) they hold.

Listing Status

The shares of Ennature Bio Pharma Limited and IGL Spirits Limited are expected to be listed on both the National Stock Exchange (NSE) and the BSE. This is subject to obtaining all necessary regulatory approvals.

Risks to watch

Potential risks include delays in regulatory approvals for listing the new entities, market reception to the demerged businesses, and ensuring smooth operational transition for each independent company.

Peer comparison

Demergers are common strategic moves in the Indian market to unlock shareholder value by creating focused businesses. Companies like Jubilant Life Sciences (now Jubilant Pharmova and Jubilant Ingrevia) have successfully executed similar demergers, leading to distinct valuations for their specialized businesses.